CA2027590A1 - Methode d'administration de medicaments par voie percutanee - Google Patents

Methode d'administration de medicaments par voie percutanee

Info

Publication number: CA2027590A1
Authority: CA; Canada
Prior art keywords: skin; drug; papain; localized area; patch
Prior art date: 1989-02-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2027590

Other languages

English (en)

Inventor

Robert V. Peterson

Tsung-Min Hsu

Han-Chen Lee

Don Christy

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Utah

Original Assignee

University of Utah

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-23

Filing date

1990-02-23

Publication date

1990-08-24

1990-02-23 Application filed by University of Utah filed Critical University of Utah

1990-08-24 Publication of CA2027590A1 publication Critical patent/CA2027590A1/fr

Status Abandoned legal-status Critical Current

Links

238000012377 drug delivery Methods 0.000 title claims abstract description 21
229940079593 drug Drugs 0.000 claims abstract description 137
239000003814 drug Substances 0.000 claims abstract description 137
102000004190 Enzymes Human genes 0.000 claims abstract description 102
108090000790 Enzymes Proteins 0.000 claims abstract description 102
238000002360 preparation method Methods 0.000 claims abstract description 71
238000000034 method Methods 0.000 claims abstract description 52
239000003961 penetration enhancing agent Substances 0.000 claims abstract description 40
239000003623 enhancer Substances 0.000 claims abstract description 31
230000002255 enzymatic effect Effects 0.000 claims abstract description 30
241001465754 Metazoa Species 0.000 claims abstract description 28
230000035699 permeability Effects 0.000 claims abstract description 9
239000012466 permeate Substances 0.000 claims abstract description 4
239000004365 Protease Substances 0.000 claims description 159
108090000526 Papain Proteins 0.000 claims description 152
229940055729 papain Drugs 0.000 claims description 152
235000019834 papain Nutrition 0.000 claims description 151
229940088598 enzyme Drugs 0.000 claims description 100
230000035515 penetration Effects 0.000 claims description 58
239000000126 substance Substances 0.000 claims description 41
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 39
-1 lactam compound Chemical class 0.000 claims description 28
150000001875 compounds Chemical class 0.000 claims description 25
AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
239000012528 membrane Substances 0.000 claims description 21
239000002904 solvent Substances 0.000 claims description 21
108091005804 Peptidases Proteins 0.000 claims description 15
102000035195 Peptidases Human genes 0.000 claims description 15
231100000245 skin permeability Toxicity 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 13
102000004196 processed proteins & peptides Human genes 0.000 claims description 13
108090000765 processed proteins & peptides Proteins 0.000 claims description 13
229920001184 polypeptide Polymers 0.000 claims description 12
230000001681 protective effect Effects 0.000 claims description 11
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 10
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 9
235000018417 cysteine Nutrition 0.000 claims description 9
125000000129 anionic group Chemical group 0.000 claims description 8
239000013043 chemical agent Substances 0.000 claims description 8
230000002708 enhancing effect Effects 0.000 claims description 8
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
125000002091 cationic group Chemical group 0.000 claims description 6
239000002738 chelating agent Substances 0.000 claims description 6
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 6
230000003389 potentiating effect Effects 0.000 claims description 6
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 4
QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 claims description 4
229920001213 Polysorbate 20 Polymers 0.000 claims description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
239000004094 surface-active agent Substances 0.000 claims description 4
229960001484 edetic acid Drugs 0.000 claims description 3
238000003860 storage Methods 0.000 claims description 3
LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 3
NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical group CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 claims description 2
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 2
229960002446 octanoic acid Drugs 0.000 claims description 2
239000002250 absorbent Substances 0.000 claims 4
230000002745 absorbent Effects 0.000 claims 4
239000007975 buffered saline Substances 0.000 claims 3
235000019441 ethanol Nutrition 0.000 claims 2
125000005909 ethyl alcohol group Chemical group 0.000 claims 1
210000003491 skin Anatomy 0.000 description 145
241000699666 Mus <mouse, genus> Species 0.000 description 47
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 31
238000011282 treatment Methods 0.000 description 29
230000000694 effects Effects 0.000 description 28
239000003795 chemical substances by application Substances 0.000 description 25
HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 23
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 22
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
239000000243 solution Substances 0.000 description 19
210000004379 membrane Anatomy 0.000 description 18
235000018102 proteins Nutrition 0.000 description 15
102000004169 proteins and genes Human genes 0.000 description 15
108090000623 proteins and genes Proteins 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
238000011084 recovery Methods 0.000 description 14
230000000740 bleeding effect Effects 0.000 description 12
229960000890 hydrocortisone Drugs 0.000 description 12
239000000853 adhesive Substances 0.000 description 11
230000001070 adhesive effect Effects 0.000 description 11
102000004877 Insulin Human genes 0.000 description 10
108090001061 Insulin Proteins 0.000 description 10
239000004480 active ingredient Substances 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
229940125396 insulin Drugs 0.000 description 10
230000001965 increasing effect Effects 0.000 description 9
239000007788 liquid Substances 0.000 description 9
210000000434 stratum corneum Anatomy 0.000 description 9
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 8
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 8
102000016943 Muramidase Human genes 0.000 description 8
108010014251 Muramidase Proteins 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 8
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 8
230000003213 activating effect Effects 0.000 description 8
238000009792 diffusion process Methods 0.000 description 8
239000008103 glucose Substances 0.000 description 8
229960000274 lysozyme Drugs 0.000 description 8
239000004325 lysozyme Substances 0.000 description 8
235000010335 lysozyme Nutrition 0.000 description 8
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 8
229960002646 scopolamine Drugs 0.000 description 8
230000002485 urinary effect Effects 0.000 description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 7
239000000006 Nitroglycerin Substances 0.000 description 7
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
230000008859 change Effects 0.000 description 7
229940079919 digestives enzyme preparation Drugs 0.000 description 7
229960003711 glyceryl trinitrate Drugs 0.000 description 7
230000008591 skin barrier function Effects 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 6
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 6
230000004907 flux Effects 0.000 description 6
229960004716 idoxuridine Drugs 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
108010004032 Bromelains Proteins 0.000 description 5
150000001408 amides Chemical class 0.000 description 5
229940098773 bovine serum albumin Drugs 0.000 description 5
235000019835 bromelain Nutrition 0.000 description 5
239000010410 layer Substances 0.000 description 5
230000000149 penetrating effect Effects 0.000 description 5
108010088751 Albumins Proteins 0.000 description 4
102000009027 Albumins Human genes 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
229960004266 acetylcholine chloride Drugs 0.000 description 4
239000000470 constituent Substances 0.000 description 4
239000011521 glass Substances 0.000 description 4
150000003951 lactams Chemical group 0.000 description 4
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 4
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 3
102000003846 Carbonic anhydrases Human genes 0.000 description 3
108090000209 Carbonic anhydrases Proteins 0.000 description 3
108090000317 Chymotrypsin Proteins 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108010003272 Hyaluronate lyase Proteins 0.000 description 3
102000001974 Hyaluronidases Human genes 0.000 description 3
229920002367 Polyisobutene Polymers 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 3
239000013543 active substance Substances 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
229960002213 alprenolol Drugs 0.000 description 3
PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
229960002376 chymotrypsin Drugs 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000009977 dual effect Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
229960002773 hyaluronidase Drugs 0.000 description 3
239000000463 material Substances 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
239000002480 mineral oil Substances 0.000 description 3
235000010446 mineral oil Nutrition 0.000 description 3
229940055577 oleyl alcohol Drugs 0.000 description 3
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 3
239000004382 Amylase Substances 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
102000029816 Collagenase Human genes 0.000 description 2
108060005980 Collagenase Proteins 0.000 description 2
102000007260 Deoxyribonuclease I Human genes 0.000 description 2
108010008532 Deoxyribonuclease I Proteins 0.000 description 2
102000016911 Deoxyribonucleases Human genes 0.000 description 2
108010053770 Deoxyribonucleases Proteins 0.000 description 2
108090000270 Ficain Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
108010019160 Pancreatin Proteins 0.000 description 2
108010023197 Streptokinase Proteins 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
239000012790 adhesive layer Substances 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229960002424 collagenase Drugs 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
229960001760 dimethyl sulfoxide Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
235000019836 ficin Nutrition 0.000 description 2
POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
230000000774 hypoallergenic effect Effects 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
229940055695 pancreatin Drugs 0.000 description 2
231100000435 percutaneous penetration Toxicity 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
238000011160 research Methods 0.000 description 2
238000003345 scintillation counting Methods 0.000 description 2
239000013464 silicone adhesive Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
229960004533 streptodornase Drugs 0.000 description 2
229960005202 streptokinase Drugs 0.000 description 2
150000003462 sulfoxides Chemical class 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
229960001322 trypsin Drugs 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
229960005080 warfarin Drugs 0.000 description 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
GCAJDUHNFZFJNX-UHFFFAOYSA-N 2,3-dihydroxypropyl octadecanoate;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO GCAJDUHNFZFJNX-UHFFFAOYSA-N 0.000 description 1
ZRYDPLOWJSFQAE-UHFFFAOYSA-N 2-tert-butylcyclohexan-1-one Chemical class CC(C)(C)C1CCCCC1=O ZRYDPLOWJSFQAE-UHFFFAOYSA-N 0.000 description 1
CFYIUBWVKZQDOG-UHFFFAOYSA-N 4-[[2-[[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-oxobutanoic acid Chemical compound C=1C=C([N+]([O-])=O)C=CC=1NC(=O)C(NC(=O)CNC(=O)CNC(=O)CCC(=O)O)CC1=CC=CC=C1 CFYIUBWVKZQDOG-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
102100034866 Kallikrein-6 Human genes 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
102100030647 Transcription factor-like 5 protein Human genes 0.000 description 1
BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
150000003869 acetamides Chemical class 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
208000009621 actinic keratosis Diseases 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000002390 adhesive tape Substances 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
229940050528 albumin Drugs 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
230000002009 allergenic effect Effects 0.000 description 1
108010027597 alpha-chymotrypsin Proteins 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
230000001760 anti-analgesic effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000002579 antinauseant Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000011717 athymic nude mouse Methods 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
229940072645 coumadin Drugs 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
238000005755 formation reaction Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
235000001510 limonene Nutrition 0.000 description 1
229940087305 limonene Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940017219 methyl propionate Drugs 0.000 description 1
229940066491 mucolytics Drugs 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
238000011328 necessary treatment Methods 0.000 description 1
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
238000005192 partition Methods 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000002985 plastic film Substances 0.000 description 1
229920006255 plastic film Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920006267 polyester film Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
231100000916 relative toxicity Toxicity 0.000 description 1
230000004044 response Effects 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
230000037390 scarring Effects 0.000 description 1
230000037380 skin damage Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000013271 transdermal drug delivery Methods 0.000 description 1
KMMBACZABOAUFF-UHFFFAOYSA-M triethyl(tetradecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](CC)(CC)CC KMMBACZABOAUFF-UHFFFAOYSA-M 0.000 description 1
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
229940117972 triolein Drugs 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Dermatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Media Introduction/Drainage Providing Device (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA 2027590 1989-02-23 1990-02-23 Methode d'administration de medicaments par voie percutanee Abandoned CA2027590A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US352,926		1982-02-26
US31481989A	1989-02-23	1989-02-23
US314,819		1989-02-23
US35292689A	1989-05-18	1989-05-18

Publications (1)

Publication Number	Publication Date
CA2027590A1 true CA2027590A1 (fr)	1990-08-24

Family

ID=26979569

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2027590 Abandoned CA2027590A1 (fr)	1989-02-23	1990-02-23	Methode d'administration de medicaments par voie percutanee

Country Status (5)

Country	Link
EP (1)	EP0418341A4 (fr)
JP (1)	JPH03505835A (fr)
AU (1)	AU5190790A (fr)
CA (1)	CA2027590A1 (fr)
WO (1)	WO1990009809A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6019988A (en) *	1996-11-18	2000-02-01	Bristol-Myers Squibb Company	Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage
WO2000038732A1 (fr) *	1998-12-23	2000-07-06	Esparma Gmbh	Hyaluronate lyase utilisee dans des medicaments topiques comme agent facilitant leur penetration
DE19923427A1 (de)	1999-05-21	2000-11-23	Lohmann Therapie Syst Lts	Vorrichtung und Verfahren zur Steigerung der transdermalen Permeation von Arzneistoffen
WO2000074762A1 (fr) *	1999-06-07	2000-12-14	Evgeny Filippovich Soloviev	Procede permettant de traiter un patient et/ou d'exercer une action therapeutique sur celui-ci
GB0128629D0 (en) *	2001-11-29	2002-01-23	Univ Sheffield	Method
WO2008108209A1 (fr) *	2007-03-01	2008-09-12	Cosmed Pharmaceutical Co., Ltd.	Préparation absorbable par voie percutanée et son procédé de production et procédé d'absorption percutanée
EP2399607B1 (fr) *	2009-02-18	2017-11-29	Hisamitsu Pharmaceutical Co., Inc.	Préparation transdermique
JP5700810B2 (ja) *	2011-03-24	2015-04-15	リンテック株式会社	経皮吸収型貼付剤キット
MX2019014052A (es) *	2017-06-02	2020-07-28	Casemed Eng	Aplicador polivalente sin contacto con deposito.
CN114557928B (zh) *	2022-03-01	2023-09-29	上海联衡生物科技有限公司	一种美白祛黄护肤品及其制备方法
CN114569513B (zh) *	2022-03-24	2023-10-13	上海联衡生物科技有限公司	一种祛痘抑菌护肤品及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2976212A (en) *	1956-12-01	1961-03-21	Schenley Ind Inc	Hyaluronidase with heparin or heparinoids in ointment compositions
GB845841A (en) *	1957-12-19	1960-08-24	Friedrich Meyer	Percutaneous administration of physiologically active agents
US3029187A (en) *	1958-02-20	1962-04-10	Steinhardt Amos	Gelating adhesive pharmaceutical preparations
US4600574A (en) *	1984-03-21	1986-07-15	Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte	Method of producing a tissue adhesive
US4668228A (en) *	1985-03-12	1987-05-26	Johnson & Johnson Products, Inc.	Debriding tape
US4690683A (en) *	1985-07-02	1987-09-01	Rutgers, The State University Of New Jersey	Transdermal varapamil delivery device
US4764379A (en) *	1987-08-24	1988-08-16	Alza Corporation	Transdermal drug delivery device with dual permeation enhancers
US4867981A (en) *	1987-11-19	1989-09-19	Henry Greenwald	Tape releasing composition and method of using same

1990
- 1990-02-23 EP EP19900904154 patent/EP0418341A4/en not_active Withdrawn
- 1990-02-23 CA CA 2027590 patent/CA2027590A1/fr not_active Abandoned
- 1990-02-23 WO PCT/US1990/000998 patent/WO1990009809A1/fr not_active Ceased
- 1990-02-23 AU AU51907/90A patent/AU5190790A/en not_active Abandoned
- 1990-02-23 JP JP2504418A patent/JPH03505835A/ja active Pending

Also Published As

Publication number	Publication date
EP0418341A4 (en)	1992-02-19
JPH03505835A (ja)	1991-12-19
EP0418341A1 (fr)	1991-03-27
WO1990009809A1 (fr)	1990-09-07
AU5190790A (en)	1990-09-26

Publication	Publication Date	Title
US5296222A (en)	1994-03-22	Percutaneous drug delivery system
Smith et al.	1995	Percutaneous penetration enhancers
US5534260A (en)	1996-07-09	Percutaneous drug delivery system
Ranade	1991	Drug delivery systems. 6. Transdermal drug delivery
CA1329547C (fr)	1994-05-17	Compositions stimulant la penetration transcutanee au moyen du mono-oleate de glycerine
Magnusson et al.	2001	Veterinary drug delivery: potential for skin penetration enhancement
Chien	1987	Development of transdermal drug delivery systems
US5238933A (en)	1993-08-24	Skin permeation enhancer compositions
KR0143916B1 (ko)	1998-07-15	약물/침투 증대제 조성물과 관련된 피부자극의 감소방법
US4933184A (en)	1990-06-12	Menthol enhancement of transdermal drug delivery
JP2655983B2 (ja)	1997-09-24	チロシナーゼ抑制活性を有する薬物の安定性を改善する方法、及び、皮膚美白用貼付剤
CA2217888C (fr)	2001-08-28	Utilisation de la triacetine comme stimulation de penetration transdermique
JP2660839B2 (ja)	1997-10-08	局所塗布用浸透促進製薬組成物
JP5016163B2 (ja)	2012-09-05	薬物の経皮透過性を増大させるためのデバイスおよび方法
KR890000183B1 (ko)	1989-03-09	경피 침투가 증진된 생리학적 활성 제제 및 그의 제조방법
TW427908B (en)	2001-04-01	Pharmaceutical composition for the treatment of fungal diseases in nails and bandages containing the same
JP2003525641A (ja)	2003-09-02	爪真菌症の治療用感圧接着性マトリックス・パッチ
ATE258426T1 (de)	2004-02-15	Zusammensetzungen und verfahren zur topischen anwendungen von wirkstoffen
EP1542695A1 (fr)	2005-06-22	Composition pharmaceutique pour l'administration topique de meloxicam, qui contient une amine ou un amide comme agent facilitant la penetration
US5156846A (en)	1992-10-20	Percutaneous drug delivery system
CA2027590A1 (fr)	1990-08-24	Methode d'administration de medicaments par voie percutanee
HUP0201299A2 (en)	2002-08-28	Device for topical treatment of acne and its method of manufacture
WO1993023019A1 (fr)	1993-11-25	Dispositifs d'apport medicamenteux transcutane, compositions qui y sont associees et procedes d'utilisation
CZ2002488A3 (cs)	2002-06-12	Transdermální podávání lasofoxifenu
Chien	1991	Systemic delivery of pharmacologically active molecules across the skin

Legal Events

Date	Code	Title	Description
1992-08-23	FZDE	Dead